|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We analyzed the effect of anti-EGFR monoclonal antibodies (mAbs; cetuximab and panitumumab) in combination with chemotherapeutic agents (docetaxel, cisplatin, and epirubicin) on EGFR-expressing TNBC cell lines that have different mutation statuses for one oncogene (KRAS) and two tumor suppressor genes (PTEN and BRCA1).
|
27864890 |
2017 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
'BRCAness' is a term used to describe cancer cells that behave similarly to tumors with BRCA1 or BRCA2 mutations.
|
29620483 |
2018 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Sequencing of BRCA1 amplified from genomic DNA of lymphocytes and microdissected ovarian tumor cells of a familial ovarian cancer patient revealed three, rare heterozygous DNA variations (2418delA, 233G-->A, and IVS1-10T-->C) in both tumor and constitutional (lymphocyte) DNA.
|
10459348 |
1999 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We also discuss the impact of BRCA1 hypermethylation, as a form of epigenetic change, versus BRCA1 genetic mutations in tumour development.
|
12191635 |
2002 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Intensive surveillance may not detect breast carcinoma at an early, curable stage in young women with BRCA1 or BRCA2 gene mutations because the growth rate of the tumors in these women most likely will be rapid and the density of the breast tissue may compromise detection.
|
10630176 |
1999 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
This locus has been associated with frequent loss of heterozygosity (LOH) and allelic imbalance in breast cancers; however, BRCA1 mutations are rare events in sporadic breast cancer with LOH in the region, suggesting that another tumor suppressor gene resides in this area.
|
16538531 |
2006 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Consistent with earlier studies, TP53 mutations were present in the majority (96.6%) of the tumors studied, and mutations in BRCA1/2 that affect DNA repair were also detected frequently in 20.5% of the tumors.
|
31124283 |
2019 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Patients and Methods Plasma and tumor samples were obtained from 30 patients with HGSC with either BRCA1 or BRCA2 germline mutation.
|
28414925 |
2017 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In this review, we discuss how the discovery of BRCA1 and BRCA2 has not only provided an understanding of the molecular processes that drive tumourigenesis but also reignited an interest in therapeutically exploiting loss-of-function alterations in tumour suppressor genes.
|
27528623 |
2016 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Three of 32 tumors (9%) had pathogenic (ARUP class-5) BRCA1 gene alterations.
|
29453630 |
2018 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Germ-line mutations in the tumour suppressor proteins BRCA1 and BRCA2 predispose to breast and ovarian cancer.
|
20437199 |
2010 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Loss of heterozygosity on Xp was twice as common in tumor DNA from germline BRCA1 mutation carriers (9/14 vs 19/67, P = 0.02).
|
10684722 |
2000 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The recent approval of olaparib (Lynparza), the poly (ADP-ribose) polymerase (PARP) inhibitor for treating tumors harboring BRCA1 or BRCA2 mutations, represents the first medicine based on this principle, exploiting an underlying cause of tumor formation that also represents an Achilles' heel.
|
26590714 |
2015 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Furthermore, p53 mutation and EGFR overexpression occur similarly in BRCA1-mutated and basal-like cancers; these shared alterations provide very important information for understanding not only the genetic and epigenetic carcinogenic pathways in these tumors but also therapeutic strategies.
|
18946749 |
2008 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We observed a prevalence of highly proliferating tumors when the mutation occurs in the two terminal conserved domains of the BRCA1 protein, ie., in the amino and carboxyl termini (P = 0.0024).
|
8764110 |
1996 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Approximately 20% of high-grade serous ovarian cancers are homologous-recombination (HR)-deficient due to genetic and epigenetic mutations of HR pathway genes including the tumor suppressor genes BRCA1 and 2.
|
28866885 |
2017 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
DNA extracted from the tumor specimens was analyzed for the three founder mutations in BRCA1 and BRCA2.
|
17625123 |
2007 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
BRCA1/2 mutation carriers diagnosed with breast cancer have a strongly elevated life-time risk of developing a contralateral tumour.
|
10917555 |
2000 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Loss of heterozygosity (LOH) of BRCA1, a tumor suppressor gene, is one mechanism of genetic inactivation in both sporadic and familial forms of breast cancer.
|
11029525 |
2000 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In contrast, there is emerging evidence of relative resistance of tumors containing BRCA1 or BRCA2 mutations (or BRCAness) to taxanes.
|
23881989 |
2013 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Breast cancers in BRCA1 gene mutation carriers often have specific histologic features: grade III tumors with pushing margins.
|
16924440 |
2006 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Prevalence of Jewish founder mutations in BRCA1 and BRCA2 was only 4.3% of patients with borderline tumors as compared to 24.2% of patients with early stage ovarian cancer (P = 0.001).
|
15893369 |
2005 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The BRCA1 region is also subject to allelic loss in sporadic breast and ovarian cancers, an indication that BRCA1 mutations may occur somatically in these tumors.
|
7939630 |
1994 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Triple-negative tumor status was highly predictive of BRCA1 mutation status for women younger than 50 years (LR = 3.73 (3.43 to 4.05)) and 50 years or older (LR = 4.41 (3.86 to 5.04)), and modestly predictive of positive BRCA2 mutation status in women 50 years or older (LR = 1.79 (1.42 to 2.24)).
|
25857409 |
2014 |
|
Neoplasms
|
0.500 |
GeneticVariation
|
group |
BEFREE |
We conclude that MYB amplification is infrequent in sporadic breast cancer but common in breast tumors from BRCA1 mutation carriers, suggesting a role of this cell cycle regulator and transcription factor in the progression of some BRCA1 tumors.
|
11034064 |
2000 |